Table 1 Summary of Clinical Characteristics of LGG Patients Who Undergo Recurrence
Characteristic | All Patients, N = 106 |
|---|---|
Age, years | |
Average | 40.09 |
Range | 18–70 |
Gender, n (%) | |
Female | 32 (30.2%) |
Male | 74 (69.8%) |
Location, n (%) | |
Frontal | 38 (35.9%) |
Temporal | 21 (19.8%) |
Multi | 28 (26.4%) |
Other | 19 (17.9%) |
Initial symptom, n (%) | |
Epilepsy | 56 (52.8%) |
Other | 50 (47.2%) |
First diagnosed grade, n (%) | |
WHO II | 77 (72.6%) |
WHO III | 29 (27.4%) |
First diagnosed pathology type, n (%) | |
Astrocytoma | 62 (58.5%) |
Oligodendroglial | 44 (41.5%) |
Malignant transform, n (%) | |
Yes | 33 (31.1%) |
No | 73 (68.9%) |
P53, n (%) | |
Mutant | 77 (72.6%) |
Wide | 29 (27.4%) |
1p/19q Codeletion, n (%) | |
Yes | 47 (44.3%) |
No | 59 (55.7%) |
IDH1-R132H, n (%) | |
Mutant | 73 (68.9%) |
Wide | 33 (31.1%) |
ATRX, n (%) | |
Mutant | 66 (62.3%) |
Wide | 40 (37.7%) |
Ki-67, n | |
Average | 17.04 |
Range | 0–80 |
Adjuvant therapy, n (%) | |
Stupp | 68 (64.2%) |
Other | 38 (35.8%) |
Blood work, average (IQR) | |
NLR, | 2.820 (0.667–21.298) |
PLR, | 128.653 (41.026–578.723) |
LMR, | 4.191 (0.181–21.667) |
RDW, % | 13.65 (12.0–23.6) |
FIB, g/L | 2.74 (1.26–14.30) |
DD, mg/L | 0.160 (0.005–1.080) |
TTR, days | |
Average | 1806.58 |
Range | 177–6310 |
PRS, days | |
Average | 768.86 |
Range | 39–1981 |
OS, days | |
Average | 2575.43 |
Range | 263–8176 |
Survival Status, n (%) | |
Alive | 42 (39.6%) |
Dead | 64 (60.4%) |